Looking for the next mRNA breakthrough, Moderna taps AbCellera in mysterious antibody discovery deal
Moderna’s success with its Covid-19 vaccine has busted the dam open on a range of potential mRNA therapeutics — and now the biotech is pushing to keep the cutting edge in-house. A new partnership with standout antibody discovery outfit AbCellera could help keep the ball in the competition’s court.
Moderna will partner with antibody player AbCellera on up to six undisclosed targets for a range of mRNA-encoded drugs harvested from AbCellera’s bustling discovery platform, the companies said Wednesday.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.